Stryker's results for Q3 2026 (quarter ended Sep 30, 2026) come from the company's own earnings release, filed with the SEC on 2026-10-29. Everything below is taken from that filing; quotes are copied exactly. Company outlooks are the company's own.
At a glance
| Item | Value |
|---|---|
| Revenue (GAAP) | $6,520 million (+7.6% vs a year earlier) |
| Diluted EPS (GAAP) | $1.96 |
| Adjusted per-share figure (company's non-GAAP measure; FFO/AFFO for REITs) | $3.52 |
| Full-year guidance | Stated (no change given) |
Guidance
Stryker updated 2026 guidance to organic net sales growth of 6.5%–7.0% and adjusted EPS of $14.80–14.90; no prior figures given.
Why this label: Release says 'updating our full year 2026 guidance and now expect' organic sales growth 6.5%-7.0% and adjusted EPS $14.80-14.90; no prior figures or raise/lower words.
| Metric | Period | New | Prior (as stated in the release) |
|---|---|---|---|
| organic net sales growth | FY2026 | 6.5%–7.0% | not stated |
| adjusted net earnings per diluted share | FY2026 | $14.80–14.90 | not stated |
From the release
Revenue: "Net sales · $ · 6,520 · $ · 6,057 · 7.7 · %"
Earnings per share: "Reported net earnings per diluted share of $1.96 decreased 11.7% in the quarter."
organic net sales growth: "We are updating our full year 2026 guidance and now expect organic net sales growth (2) in the range of 6.5% to 7.0%"
adjusted net earnings per diluted share: "adjusted net earnings per diluted share (2) to be in the range of $14.80 to $14.90"
Quotes are copied from the filing; in table rows, cell borders are shown as “·”.
Key fact: Organic net sales up 7.7%; adjusted EPS up 10.3% to $3.52; reported EPS down 11.7%.
Source
Stryker earnings release (SEC filing), accession 0000310764-26-000059, filed 2026-10-29.
Part of the Q3 2026 Guidance Tracker. Educational only, not advice. Free weekly recap every Sunday: yieldterminalpro.com/newsletter.